BioMérieux: the rebound gains momentum, an analyst reinforces its case
May 10, 2024 at 01:42 pm
Share
bioMérieux's share price continues the recovery it began the previous Friday on the Paris Bourse, where, in addition to renewed market optimism, the diagnostics specialist continues to benefit from positive comments from Barclays.
After gaining more than 0.1% yesterday, the stock is now up by around 1.1% today.
In a note published the previous day, Barclays analysts indicated that they had initiated coverage of the stock with an 'overweight' recommendation and a price target of 120 euros, representing a potential upside of 20%.
The research department hails the company as a 'quality player' in a growing market, highlighting in particular its ability to grow thanks to its presence in 'multiplex' testing, where demand is holding up well.
It also praises its leading position, with a market share of around 75%, in the infectious diseases segment with its Biofire platform.
Barclays, which sees the group's profit margins improving despite continued high R&D spending, says it predicts free cash flow of over 300 million euros this year and average annual sales growth of 7% per annum by 2027.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.4%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.6%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (32.4%), North America (44.1), Asia/Pacific (17.3%) and Latin America (6.2%).
BIOMÉRIEUX 
